[The patient with rheumatoid arthritis in general practice - what needs to be considered before and during therapy?]

Q4 Medicine
Praxis Pub Date : 2025-03-01 DOI:10.23785/PRAXIS.2025.03.006
Melanie Kraus, Kriemhild Lippay
{"title":"[The patient with rheumatoid arthritis in general practice - what needs to be considered before and during therapy?]","authors":"Melanie Kraus, Kriemhild Lippay","doi":"10.23785/PRAXIS.2025.03.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease in Switzerland, affecting up to 1 % of patients. Accordingly, these patients are also frequently seen in general practitioner consultations. The first-line therapy consists of methotrexate +/- glucocorticoids. Further disease modifying antirheumatic drugs (DMARDs) are necessary depending on symptom control, disease activity and side effects. Therapy goals are 1. improving quality of life, 2. preventing bone destruction and 3. controlling inflammation and thus reducing cardiovascular mortality. Patients with RA have an increased risk of infection due to their disease and therapy. Vaccination status should be checked and screening for relevant infectious diseases should be carried out before starting treatment. This article is intended to provide an overview of the treatment options as well as screening and prophylaxis of infections in accordance with the current recommendations of the European Alliance of Associations for Rheumatology (EULAR) and the Swiss Society of Rheumatology (SGR).</p>","PeriodicalId":20494,"journal":{"name":"Praxis","volume":"114 3","pages":"105-110"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Praxis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23785/PRAXIS.2025.03.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease in Switzerland, affecting up to 1 % of patients. Accordingly, these patients are also frequently seen in general practitioner consultations. The first-line therapy consists of methotrexate +/- glucocorticoids. Further disease modifying antirheumatic drugs (DMARDs) are necessary depending on symptom control, disease activity and side effects. Therapy goals are 1. improving quality of life, 2. preventing bone destruction and 3. controlling inflammation and thus reducing cardiovascular mortality. Patients with RA have an increased risk of infection due to their disease and therapy. Vaccination status should be checked and screening for relevant infectious diseases should be carried out before starting treatment. This article is intended to provide an overview of the treatment options as well as screening and prophylaxis of infections in accordance with the current recommendations of the European Alliance of Associations for Rheumatology (EULAR) and the Swiss Society of Rheumatology (SGR).

求助全文
约1分钟内获得全文 求助全文
来源期刊
Praxis
Praxis Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
146
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信